portal
  Home About us Reports Charts News Custom Company Scan  
Report Charts News
*
Title Content
Economy&Goods
  Economy
  ConsumerGoods
  Food&Beverage
  Agriculture
Life Sciences
  Biotechnology
  Medical
  Pharmaceutical
Manufacturing
  Automotive
  Chemical
  Energy
  Machinery
  Material
  Metals & Minerals
Public Sector
  Environment
  Finance Service
  Infrastructure
  Logistics
  Real Estate
  Retailing
  Tourism
  Training
Technology And Media
  Electronics
  Internet
  Hardware
  Media
  Software
  Telecommunications

Tel: 0086-10-82600828
Fax: 0086-10-82601570
Email:


 German Watchdog Deals Setback To Bayer AG (BAYN.DE) Eye Drug Eylea
 
CreateTime:2014-01-06 Editor:liaoyan
Text Size:       
 

Bayer suffered a setback in its home market of Germany on Thursday when a healthcare cost watchdog said it was unable to assess whether its new eye medication Eylea offered an advantage over a rival product from Novartis. The opinion issued by the German Institute for Quality and Efficiency in Health Care, or IQWiG, could affect the level of reimbursement by public insurers for Eylea in Germany. IQWiG compared trial data on Eylea and Novartis's Lucentis for treatment of macular edema - a build-up of fluid under the centre of the retina following a blockage of the retina's major vein.

 


Related Reports
China Blood Product Industry Report, 2020-2027
China Medical Robot Industry Report, 2020-2026
China In Vitro Diagnostic (IVD) Industry Report, 2019-2025
China Aged Care Industry Report, 2019-2025
China Dental Industry Report, 2019-2025
2005-2021 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1